Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Open-Label, Dose-Escalation Study of Tivozanib (AV-951) Plus FOLFOX6 in Subjects With Advanced Colorectal Cancer and Other Gastrointestinal Cancers

NCT00660153 is registered in ClinicalTrials.gov with AVEO Pharmaceuticals, Inc. as lead sponsor.

NCT NCT00660153
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00660153 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Open-Label, Dose-Escalation Study of Tivozanib (AV-951) Plus FOLFOX6 in Subjects With Advanced Colorectal Cancer and Other Gastrointestinal Cancers
Lead sponsor
AVEO Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2008
Completion date
June 30, 2012
Enrollment
30 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, gastrointestinal cancer